Sangamo’s Macrae on where the gene editing field is headed: a BioCentury audio interview

Gene-editing assets may be the next additions to big pharma shopping lists as gene therapies are now becoming core modalities alongside small molecules and mAbs, according to Sandy Macrae, who anticipates a gene editing consolidation in the coming years. 

Macrae, who joined Sangamo Therapeutics Inc. (NASDAQ:SGMO) as president and CEO in 2016, discussed his view of the challenges and opportunities in gene editing in a BioCentury This Week – Special Edition audio interview...